Formycon - Termination of coverage
Edison Investment Research is terminating coverage on:• 2G Energy (2GB)
• Apontis Pharma (APPH)
• Artec technologies (A6T)
• Beta Systems (BSSA)
• Blue Cap (B7E)
• Cyan (CYR)
• Consus Real Estate (CC1)
• Daldrup & Soehne (4DS)
• DATAGROUP (D6H)
• Datron (DAR)
• Delignit (DLX)
• Deutsche Börse (DB1)
• Deutsche Grundstücksauktionen (DGR)
• Deutsche Rohstoff (DR0)
• DVS Technology (DIS)
• Edel (EDL)
• Ernst Russ (HXCK)
• Exasol (EXL)
• expert.ai (EXAI/EXSY)
• Fashionette (FSNT)
• Formycon (FYB)
• Forward Industries (FORD)
• Helma Eigenheimbau (H5E)
• IBU-tec (IBU)
• JDC Group (JDC)
• Lloyd Fonds (L1OA)
• Media and Games Invest (M8G)
• Mensch & Maschine Software (MUM)
• mic (M3B)
• MPC Münchmeyer Peterson/MPC Capital (MPCK)
• mVISE (C1VX)
• Nabaltec (NTG)
• Noratis (NUVA)
• Nürnberger Beteiligungs (NBG6)
• Nynomic (M7U)
• Ökoworld/Oekoworld (VVV3)
• PANTAFLIX (PAL)
• publity (PBY)
• RCM Beteiligungs (RCM)
• Scherzer & Co (PZS)
• SGT German Private Equity (SGF)
• The NAGA Group (N4G)
• Vectron Systems (V3S)
• Veganz (VEZ)
Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.
Previously published reports can still be accessed via our website.
Formycon AG is a Germany-based company engaged in providing biosimilar drugs and formulations. Its business activities are focused on the development and marketing of biopharmaceuticals that are similar to existing drugs, for which the patent protection is expiring. The Company focuses on treatments in the area of ophthalmology, immunology and other chronic diseases, covering all steps of biosimilar development process, from early-stage analysis of the originator drug to the preclinical and clinical testing phases, as well as the preparation of dossiers for marketing approval. Its biosimilar product pipeline consists of four candidates in pre-clinical and clinical testing phases, including FYB201, a biosimilar candidate for Lucentis; FYB202, a biosimilar candidate for Stelara; FYB203, a biosimilar candidate for Eylea, and FYB205.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.